FibroGen Inc. Releases Proforma Financials Following $220 Million Sale of FibroGen China to AstraZeneca
FibroGen Inc. has released its unaudited pro forma condensed consolidated financial statements in connection with its recent transaction involving the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. The transaction, valued at approximately $220 million, includes $85 million in enterprise value and about $135 million in net cash held in China. The financial statements, prepared in accordance with Article 11 of Regulation S-X, illustrate the impact of this transaction on FibroGen's historical financials. At the closing, FibroGen also repaid its $81 million senior secured term loan with Morgan Stanley Tactical Value and entered into a transition services agreement, among other customary agreements. The pro forma statements provide insights into the financial adjustments and anticipated outcomes of this significant M&A activity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921299-25-000007), on September 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。